CTAD Boston 2-4, 2017
Alzheimer’s disease is one of the most important health challenges facing aging populations worldwide. The development of the next generation of Alzheimer’s disease drugs is becoming essential to face up to this challenge.
This online abstract submission will close on June 8, 2017. No late abstracts will be accepted. Presenting authors will be notified of the Scientific Committee's decision regarding acceptance of their abstracts.
The presenting author must be registered to CTAD 2017 by August 1, 2017.
Presentations will be organized by themes, please indicate on your submission which theme you are submitting for:
1. Clinical trials : methodology
2. Clinical trials : results
3. Clinical trials : imaging
4. Clinical trials : biomarkers including plasma
5. Clinical trials : cognitive and functional endpoints
6. Cognitive assessment and clinical trials
7. Behavioral disorders and clinical trials
8. Health economics and clinical trials
9. Epidemiology and clinical trials
10. Animal model and clinical trial
11. New therapies and clinical trials
All presenting authors, including the symposium moderator, must be registered to CTAD 2017. If all authors are not registered by August 1, 2017 the organizing committee can cancel the symposium.
If your abstract is not selected for a symposium it will automatically be considered for an oral communication and you will be asked to resubmit and abstract to fit the “oral communication” format.
Abstracts accepted for presentation at CTAD 2017 will be published in a special issue of the Journal of Prevention of Alzheimer’s Disease (http://www.jpreventionalzheimer.com/) after the event. It is thus essential to follow the instructions in preparing your abstract, abstracts submitted in an inappropriate format will not be considered for presentation. The word document you attach must include all authors and affiliations, it is the document that will be used for publication